ADC Therapeutics SA (ADCT) · Oct 13, 2026 · Restructuring

ADC Therapeutics debt amendment cuts loan to $50M, buys time

Debt restructured — $50M outstanding; no scheduled amortization before maturity

ADC Therapeutics’ debt amendment reduces term loans to $50 million, removes scheduled amortization and eases liquidity pressure as ZYNLONTA remains its core asset.

ADC Therapeutics is now a commercial-stage biotech concentrating resources on its ZYNLONTA lymphoma franchise after a strategic reorganization, while pursuing additional indications through LOTIS-5 and LOTIS-7. This filing is balance-sheet repair, not a new operating catalyst. The broad restructuring was already announced on October 8, 2026, so the surprise is limited; this document supplies the legal mechanics that make the package workable.

Filing itemChangeFiling comparison
Term loans after prepayment$50.0 millionExisting debt is partially prepaid; exact prepayment amount is not disclosed
Scheduled principal amortizationNone before maturityVoluntary or mandatory prepayments and acceleration rights remain
Minimum liquidity covenant$60.0 million plus Qualified Cash A/P Amount before effectiveness; no testing after effectivenessCovenant relief begins only once the amendment becomes effective
Minimum U.S. ZYNLONTA sales$65.0 million from December 31, 2026 onwardDown from $68.923 million for the September 30, 2026 quarter

The main improvement is near-term cash flexibility. ADC will prepay debt down to $50 million, then eliminate scheduled principal installments until maturity. 〔0〕 〔1〕 That gives the company more room to fund ZYNLONTA commercialization and clinical work instead of making fixed quarterly debt payments, although the filing does not disclose the cash paid, remaining maturity, or resulting runway.

The covenant reset also acknowledges that the commercial ramp remains demanding. The minimum U.S. ZYNLONTA sales schedule rises to $68.9 million through September 2026, then resets to $65 million for December 2026 and later quarters (Minimum U.S. ZYNLONTA Sales schedule). That is less aggressive than the immediately preceding threshold, but it is still a lender-imposed sales hurdle for a company whose core product performance remains central to its financing capacity.

The trade-off is that lenders keep substantial protection. The amendment preserves acceleration rights, keeps collateral and security interests in place, requires the debt to be repaid at maturity or upon acceleration, and permits a future Delaware redomiciliation only under detailed conditions. The liquidity covenant disappears only after the amendment becomes effective; that date must occur by October 31, 2026 unless lenders extend it. 〔2〕

Bottom line: This turns a near-term debt-payment problem into a more manageable $50 million maturity obligation and modestly lowers the ZYNLONTA sales hurdle. It materially supports the restructuring story, but it is mostly confirmation of an already-announced financing plan rather than a fresh business inflection point.

What to watch next

Second Amendment Effective Date, due by October 31, 2026

Original filing on SEC EDGAR

More ADC Therapeutics SA news

ADC Therapeutics debt amendment cuts loan to $50M, buys time | ADCT Stock News
AllSight

Breaking down Wall Street's
information edge.

A buy-side analyst on every ticker — it reads every public company's filing the instant it drops and decodes it into plain English.

—
8-K events this week
—
filings analyzed in total
live · updated 30s ago
Live events · whole market · · --:--:-- ET
AllSight read
Straight from the 8-K
Verbatim from the filing AllSight decoded — highlighted above. Open on SEC EDGAR ↗
Limited-time offerFree 14-day Pro trial
AllSight

Sign in to AllSight

  • Follow any company — we email you the moment it files, free!
  • Your watchlist saved to your account, on every device — free!

by Signing in NOW, claim your FREE 14-day Pro trial!

No password. We email you a 6-digit code. By continuing you agree to our Terms & Privacy.
AllSight · Live plain-English 8-K decodes across the whole US market · Not investment advice.